Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Pediatric Patients (28 Days to ≤ 18 Years of Age.) With High-Risk Hematopoietic Stem Cell Transplant Thrombotic Microangiopathy

NCT05855083 is registered in ClinicalTrials.gov with Omeros Corporation as lead sponsor.

NCT NCT05855083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05855083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Pediatric Patients (28 Days to ≤ 18 Years of Age.) With High-Risk Hematopoietic Stem Cell Transplant Thrombotic Microangiopathy
Lead sponsor
Omeros Corporation
Phase
Phase 2
Overall status
Recruiting
Start date
May 1, 2023
Completion date
December 31, 2025
Enrollment
18 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic stem cell transplantation, thrombotic microangiopathies